share_log

Weak Statutory Earnings May Not Tell The Whole Story For Winning Health Technology Group (SZSE:300253)

Weak Statutory Earnings May Not Tell The Whole Story For Winning Health Technology Group (SZSE:300253)

疲弱的法定收益可能不能説明贏得健康科技集團(SZSE:300253)的全部故事
Simply Wall St ·  2022/04/30 20:40

A lackluster earnings announcement from Winning Health Technology Group Co., Ltd. (SZSE:300253) last week didn't sink the stock price. However, we believe that investors should be aware of some underlying factors which may be of concern.

一份平淡無奇的財報贏利健康科技集團有限公司。(SZSE:300253)上週股價並未下跌。然而,我們認為投資者應該意識到一些可能令人擔憂的潛在因素。

View our latest analysis for Winning Health Technology Group

查看我們贏得健康科技組的最新分析

SZSE:300253 Earnings and Revenue History May 1st 2022
深圳證交所:300253盈利和收入歷史2022年5月1日

The Impact Of Unusual Items On Profit

異常項目對利潤的影響

To properly understand Winning Health Technology Group's profit results, we need to consider the CN¥145m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. We can see that Winning Health Technology Group's positive unusual items were quite significant relative to its profit in the year to March 2022. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

要正確理解贏利健康科技集團的盈利業績,我們需要考慮歸因於異常項目的1.45億元人民幣收益。我們不能否認,更高的利潤通常會讓我們保持樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們分析全球絕大多數上市公司時,我們發現重大的不尋常項目往往不會重複。考慮到這個名字,這並不令人驚訝。我們可以看到,在截至2022年3月的一年中,獲獎健康科技集團的積極異常項目與其利潤相比相當重要。因此,我們可以推測,這些不尋常的項目使其法定利潤比其他情況下要強勁得多。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道,分析師對未來盈利能力的預測是什麼。幸運的是,您可以單擊此處查看基於他們估計的未來盈利能力的互動圖表。

Our Take On Winning Health Technology Group's Profit Performance

我們對贏得健康科技集團盈利業績的看法

As previously mentioned, Winning Health Technology Group's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Winning Health Technology Group's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 20% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Winning Health Technology Group as a business, it's important to be aware of any risks it's facing. For example, we've discovered 3 warning signs that you should run your eye over to get a better picture of Winning Health Technology Group.

正如前面提到的,從不尋常的項目中贏得健康科技集團的巨大提振不會無限期地存在,因此該集團的法定收益可能是衡量其潛在盈利能力的糟糕指標。因此,我們認為很可能是贏利健康科技集團的潛在盈利能力低於其法定利潤。但至少持有者可以從過去三年每股收益每年20%的增長中得到一些安慰。當然,當談到分析其收益時,我們只是觸及了皮毛;人們還可以考慮利潤率、預測增長和投資回報等因素。如果你想了解更多關於贏得健康科技集團的業務,重要的是要意識到它所面臨的任何風險。例如,我們發現了3個警告信號,你應該掃視一下,才能更好地瞭解贏得健康技術組的照片。

This note has only looked at a single factor that sheds light on the nature of Winning Health Technology Group's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

這份報告只關注了一個因素,它揭示了贏得健康科技集團利潤的本質。但還有很多其他方式可以讓你瞭解一家公司的看法。一些人認為,高股本回報率是高質量企業的良好標誌。雖然這可能需要為您做一些研究,但您可能會發現免費擁有高股本回報率的公司的集合,或者是內部人士購買的有用的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎?保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
這篇由《華爾街日報》撰寫的文章本質上是籠統的。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。簡單地説,華爾街在提到的任何股票中都沒有頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論